Frontiers in Immunology (Sep 2021)
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
- Roos S. G. Sablerolles,
- Roos S. G. Sablerolles,
- Abraham Goorhuis,
- Abraham Goorhuis,
- Corine H. GeurtsvanKessel,
- Rory D. de Vries,
- Anke L. W. Huckriede,
- Marion P. G. Koopmans,
- Melvin Lafeber,
- Douwe F. Postma,
- Debbie van Baarle,
- Debbie van Baarle,
- Leo G. Visser,
- Virgil A. S. H. Dalm,
- Neeltje A. Kootstra,
- Wim J. R. Rietdijk,
- P. Hugo M. van der Kuy
Affiliations
- Roos S. G. Sablerolles
- Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
- Roos S. G. Sablerolles
- Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands
- Abraham Goorhuis
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, Netherlands
- Abraham Goorhuis
- Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, Netherlands
- Corine H. GeurtsvanKessel
- Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands
- Rory D. de Vries
- Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands
- Anke L. W. Huckriede
- Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
- Marion P. G. Koopmans
- Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands
- Melvin Lafeber
- Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
- Douwe F. Postma
- Department of Internal Medicine, University Medical Center Groningen, Groningen, Netherlands
- Debbie van Baarle
- Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
- Debbie van Baarle
- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
- Leo G. Visser
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
- Virgil A. S. H. Dalm
- 0Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
- Neeltje A. Kootstra
- 1Department of Medical Microbiology, Amsterdam University Medical Centers, Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, Netherlands
- Wim J. R. Rietdijk
- Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands
- P. Hugo M. van der Kuy
- Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands
- DOI
- https://doi.org/10.3389/fimmu.2021.753319
- Journal volume & issue
-
Vol. 12
Abstract
No abstracts available.Keywords
- SARS-CoV-2
- COVID-19
- Homologous vaccination regimen
- Heterologous vaccine regimen
- randomized clinical trial
- Ad26.Cov2.S